source
- Daraxonrasib shows 35% response rate in second‑line RAS‑mutated pancreatic cancerPhase 1/2 data from a monotherapy study of daraxonrasib in patients with RAS G12‑mutated pancreatic ductal adenocarcinoma reported an objective response rate of 35% when used as a second‑line treat…
- Blackstone invests $250 million in Anagram to address cystic fibrosis complicationBlackstone Life Sciences announced a $250 million investment in Anagram, a biotech focused on cystic fibrosis complications. The funding is part of one of the largest private investment funds in t…